Flulaval Adverse Reaction Adult

FLULAVAL QUADRIVALENT was studied in a randomized, double-blind, active-controlled immunogenicity and safety trial. Subjects aged 18 years and older received FLULAVAL QUADRIVALENT (n=1260) or 1 of 2 formulations of a comparator trivalent influenza vaccine (FLUARIX TIV-1 (n=208) or TIV-2 (n=216)), each containing an influenza type B virus that corresponded to one of the two B viruses in FLULAVAL QUADRIVALENT (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). Solicited local and systemic adverse events were collected for 7 days (day of vaccination and the next 6 days).¹